MedPath
Found 6 clinical trials|View Analysis
Sort by:

A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

Phase 2
Active, not recruiting
Conditions
Leiomyosarcoma
Interventions
First Posted Date
2022-03-08
Last Posted Date
2024-06-21
Lead Sponsor
PTC Therapeutics
Target Recruit Count
360
Registration Number
NCT05269355
Locations
🇺🇸

University of California, Los Angeles (UCLA) - Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

🇺🇸

Northwestern Memorial Hospital, Chicago, Illinois, United States

🇺🇸

The Ohio State University (OSU), Columbus, Ohio, United States

and more 51 locations

CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma

Phase 2
Recruiting
Conditions
LMS - Leiomyosarcoma
Uterine Leiomyosarcoma
Interventions
Drug: Gemcitabine
Drug: Dacarbazine
Procedure: Cytoreductive Surgery
Behavioral: Functional Assessment of Cancer Therapy (FACT) G questionnaire
Procedure: Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Scan
Drug: Gadolinium
First Posted Date
2021-01-27
Last Posted Date
2024-03-05
Lead Sponsor
Kristen Ganjoo
Target Recruit Count
25
Registration Number
NCT04727242
Locations
🇺🇸

Stanford University, Stanford, California, United States

A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)

Phase 1
Completed
Conditions
Leiomyosarcoma
Interventions
First Posted Date
2018-12-03
Last Posted Date
2024-03-15
Lead Sponsor
PTC Therapeutics
Target Recruit Count
41
Registration Number
NCT03761095
Locations
🇺🇸

John Hopkins, Baltimore, Maryland, United States

🇺🇸

Mayo Clinic Florida, Jacksonville, Florida, United States

🇺🇸

Washington University Medical Campus, Saint Louis, Missouri, United States

and more 1 locations

Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)

Phase 2
Active, not recruiting
Conditions
Soft Tissue Sarcoma
Interventions
First Posted Date
2017-04-14
Last Posted Date
2024-07-12
Lead Sponsor
Fox Chase Cancer Center
Target Recruit Count
48
Registration Number
NCT03114527
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

Conditions
Epstein-Barr Virus (EBV) Infections
Lymphoproliferative Disorders
EBV+ Associated Lymphoma
EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
Epstein-Barr Viremia
Lymphoma, AIDS-related
Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Primary Immunodeficiency (PID)
Leiomyosarcoma (LMS)
Nasopharyngeal Carcinoma (NPC)
Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Acquired Immunodeficiency (AID)
First Posted Date
2016-07-04
Last Posted Date
2023-06-15
Lead Sponsor
Atara Biotherapeutics
Registration Number
NCT02822495

Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus

Not Applicable
Completed
Conditions
Uterine Leiomyosarcoma
Uterine Cancer
Interventions
First Posted Date
2008-02-13
Last Posted Date
2015-12-22
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
25
Registration Number
NCT00614835
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath